Diabetic Nephropathy
📧 Sign up to get email alerts when something new happens for Diabetic Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: Investigational and Comparative Study in the Management of Diabetic Nephropathy [Phase 3]
A Phase 3 trial evaluating an investigational and comparative treatment for diabetic nephropathy in type 2 diabetes has completed enrollment…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: Dosimetry of Tc-99m-Tilmanocept [Phase 1]
A Phase 1 trial to assess the dosimetry of Tc-99m-Tilmanocept in diabetic nephropathy, with recruitment ongoing.
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients [Phase 4]
Phase 4 trial update evaluating dapagliflozin as add-on therapy for glycemic status and quality of life in type 2 diabetes with diabetic nep…
-
FDA approval · 2024-02-23FDA Approved: IRBESARTAN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for IRBESARTAN by Amneal Pharmaceuticals LLC.
-
FDA approval · 2024-02-16FDA Approved: IRBESARTAN — Supplemental Application (Hisun Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for IRBESARTAN from Hisun Pharmaceuticals USA Inc., approving changes to the generic product's a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-12-08Clinical Trial Update: A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study) [Phase 4]
A Phase 4 randomized trial comparing telmisartan to losartan in hypertensive patients with type 2 diabetes and overt nephropathy; completed.
-
CLINICAL_TRIALS trial_result · 2023-10-05Clinical Trial Update: Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy [Phase 2, Phase 3]
Phase 2/3 trial investigating whether low-dose aspirin protects renal function in patients with early diabetic nephropathy.
-
FDA approval · 2023-08-23FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for losartan potassium from Micro Labs Limited under an ANDA, indicating an update to the drug's app…
-
FDA approval · 2023-08-14FDA Approved: LOSARTAN POTASSIUM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the original application for losartan potassium (a generic product) by Novadoz Pharmaceuticals LLC.
-
FDA label_change · 2023-06-07FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA supplemental application for Losartan Potassium by Macleods Pharmaceuticals Limited, likely involving labeling changes for the generic d…
-
CLINICAL_TRIALS research · 2023-05-01Clinical Trial Update: Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study. [Phase 4]
Phase 4 clinical trial investigating renal oxygenation, oxygen consumption, and hemodynamic kinetics in type 2 diabetes treated with ertugli…
-
FDA label_change · 2023-03-15FDA Approved: IRBESARTAN — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for IRBESARTAN from Solco Healthcare U.S., LLC, indicating a labeling change for the product.
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy [Phase 3]
A Phase 3 clinical trial assessing pirfenidone effects on glomerular filtration rate and albuminuria in patients with diabetic nephropathy h…
-
FDA approval · 2022-11-01FDA Approved: IRBESARTAN — Supplemental Application (AvKARE)
FDA approved AvKARE's supplemental application for IRBESARTAN (irbesartan).
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy [Phase 4]
A Phase 4 trial update assessing safety and efficacy of RAAS therapy alone or with spironolactone in chronic renal insufficiency and diabeti…
-
CLINICAL_TRIALS trial_result · 2022-10-20Clinical Trial Update: Niclosamide Role in Diabetic Nephropathy [Phase 3]
Phase 3 clinical trial investigating niclosamide for diabetic nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2022-08-31Clinical Trial Update: Vitamin D Supplementation in Diabetic Nephropathy [Phase 2]
Phase 2 trial update on vitamin D supplementation in patients with diabetic nephropathy and sub-optimal vitamin D status, completed.
-
FDA approval · 2022-07-14FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Losartan Potassium by Camber Pharmaceuticals, enabling the marketing of a generic Losartan P…
-
FDA approval · 2022-07-01FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Losartan Potassium from Aurobindo Pharma Limited, authorizing changes to the approved ANDA.
-
CLINICAL_TRIALS trial_result · 2022-06-29Clinical Trial Update: Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy [Phase 2]
Phase 2 clinical trial update on Nidufexor in diabetic nephropathy reports safety, tolerability, and efficacy outcomes.
-
CLINICAL_TRIALS trial_result · 2022-05-13Clinical Trial Update: Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease [Phase 2, Phase 3]
A clinical trial comparing SGLT2 inhibitor therapy to an ACE inhibitor for diabetic nephropathy (Phase 2/3) with unknown current status.
-
CLINICAL_TRIALS research · 2022-02-15Clinical Trial Update: A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED) [Phase 3]
A Phase 3 trial evaluating whether losartan provides renal protective effects in patients with type 2 diabetes and nephropathy; the study is…
-
FDA approval · 2021-12-20FDA Approved: IRBESARTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for Irbesartan from Aurobindo Pharma Limited.
-
FDA approval · 2021-12-20FDA Approved: IRBESARTAN — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for IRBESARTAN from Unichem Pharmaceuticals (USA), Inc. for this generic product (ANDA 203020).
-
FDA approval · 2021-12-08FDA Approved: IRBESARTAN — Supplemental Application (NorthStar RxLLC)
The FDA approved a supplemental application for irbesartan from NorthStar RxLLC, authorizing changes to an existing generic product under an…